Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment

Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma

(2014) M. Atefi et al.   CLINICAL CANCER RESEARCH

The MAPK Pathway Is a Predominant Regulator of HLA-A Expression in Esophageal and Gastric Cancer

(2013) K. Mimura et al.   JOURNAL OF IMMUNOLOGY

Anti-PD1 antibody: a new approach to treatment of lymphomas

(2013) Emmanuel Bachy et al.   LANCET ONCOLOGY

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

(2013) Georgia Hatzivassiliou et al.   NATURE

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer

(2013) Minmin Song et al.   PLoS One

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

(2012) E. J. Lipson et al.   CLINICAL CANCER RESEARCH

Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity

(2011) A. Pievani et al.   BLOOD

Association of IFN-  Signal Transduction Defects with Impaired HLA Class I Antigen Processing in Melanoma Cell Lines

(2011) A. Respa et al.   CLINICAL CANCER RESEARCH

Innate or Adaptive Immunity? The Example of Natural Killer Cells

(2011) E. Vivier et al.   SCIENCE

B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma

(2009) Ryo Yamamoto et al.   CANCER SCIENCE

Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma

(2008) Y Mizukami et al.   BRITISH JOURNAL OF CANCER

Molecular mechanisms of MHC class I abnormalities and APM components in human tumors

(2008) Barbara Seliger   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tumor-Induced Immune Suppression of In vivo Effector T-Cell Priming Is Mediated by the B7-H1/PD-1 Axis and Transforming Growth Factor  

(2008) S. Wei et al.   CANCER RESEARCH

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival

(2008) David S. Alberts et al.   GYNECOLOGIC ONCOLOGY